For all of last year, Illumina’s net loss grew 5% from $1.161 billion to $1.223 billion, on revenue that fell 3% from $4.505 ...

Astellas is shifting its investment focus toward more established modalities and later-stage opportunities, its chief ...

The general mood among these heavyweight investors is divided, with 37% leaning bullish and 37% bearish. Among these notable options, 4 are puts, totaling $366,099, and 4 are calls, amounting to ...

As of 2:29:13 PM EST. Market Open.

Element Biosciences’ bid to claim a slice of a DNA sequencing technology market dominated by Illumina has been helped by an impressive $277 million financing round backed by a wide range of ...

Regeneron and Illumina have joined a major investment ... will use leftover biospecimens from routine lab tests to sequence up to ten million exomes – all of the exons in a genome that code ...

(1) Since Illumina was included in the "Unreliable Entity List", a number of domestic gene sequencing companies have issued replacement and alternative plans; (2) Illumina issued two statements in ...

Unpicking the Star Trek timeline is a thornier problem than a particularly ornery Klingon Targ. After all, Star Trek is a franchise that spans all the way from the primordial days of our universe ...

The translation of NGS technologies into clinical diagnostics is also in the early stages of development and is mainly focusing on applications that require a modest amount of genomic sequence ...

It employs recombinant DNA, DNA sequencing methods, and bioinformatics to sequence, assemble, and analyse the structure and function of genomes. A study involving 14% of the people in Greenland ...

In an X post, OpenAI CEO Sam Altman announced a timeline for GPT-5 and that the company is canceling o3 in an effort to ...